Patents by Inventor Michael O'Neill Montgomery

Michael O'Neill Montgomery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JAK1 pathway inhibitors for the treatment of cytokine-related disorders
    Patent number: 11833152
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: December 5, 2023
    Assignee: Incyte Corporation
    Inventors: Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
  • JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS
    Publication number: 20220040187
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
    Type: Application
    Filed: July 19, 2021
    Publication date: February 10, 2022
    Inventors: Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
  • JAK1 pathway inhibitors for the treatment of cytokine-related disorders
    Patent number: 11103510
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: August 31, 2021
    Assignee: Incyte Corporation
    Inventors: Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass
  • JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS
    Publication number: 20190255053
    Abstract: This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating cytokine-related diseases or disorders such as cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), and CAR-T-cell-related encephalopathy syndrome (CRES).
    Type: Application
    Filed: February 14, 2019
    Publication date: August 22, 2019
    Inventors: Michael O'Neill Montgomery, Ahmad Naim, Susan Snodgrass